Medications for osteoporosis: an update

Personalized education for health care professionals in 30-60 minutes either in-person or via web conferencing (e.g., Zoom or WebEx) at a time and location that is convenient for you. This Group Learning program has been certified by the College of Family Physicians of Canada and the British Columbia Chapter for up to 1.0 Mainpro+ credit.

Learning objective

During each academic detailing session, participants will have the opportunity to:

• Apply current evidence to guide prescribing and deprescribing decision for bisphosphonates, denosumab, raloxifene, teriparatide and romosozumab.
• Incorporate fracture risk reduction and time-to-benefit estimates as part of shared-decision making with patients.
• Compare the principal clinical considerations when choosing between bisphosphonates and denosumab, the most commonly prescribed osteoporosis medications in B.C.

After the academic detailing session, participants will be able to thoughtfully discuss, prescribe, monitor and manage the currently available osteoporosis medications in B.C.

Availability

When: Until June 4, 2025
Where: In-person at your place of work or virtual academic detailing
How: Contact your local PAD pharmacist directly or email pad@gov.bc.ca

Resources

• Handout - Medications for osteoporosis (PDF, 611KB)
• Drug table - Medications for osteoporosis (PDF, 229KB)
• References - Medications for osteoporosis (PDF, 189KB)

For more information about the PAD service, visit PAD Frequently Asked Questions.